Pfizer (PFE) News Today

Pfizer Inc. (NYSE:PFE) shares have been on the rise, driven by a series of strategic moves and positive analyst commentary. The most significant catalyst was Pfizer’s announcement of an exclusive global (ex-China) licensing agreement with China’s 3SBio for SSGJ-707, a PD-1/VEGF bispecific antibody in clinical trials. Under the deal, Pfizer agreed to up to $6 billion in payments, including a $1.25 billion upfront, to develop, manufacture, and commercialize the experimental cancer drug outside China.

Bullish analyst coverage has reinforced investor confidence. On May 20, BMO Capital’s Evan Seigerman maintained a Buy rating on PFE and kept his $30 price target unchanged, highlighting the 3SBio deal as a major growth driver. Media outlets from MarketBeat to Benzinga and CNBC noted that Pfizer was pacing for its fourth consecutive day of gains, attributing the momentum to the enlarged oncology pipeline and reassured buy-side sentiment.

Key catalysts for PFE’s recent strength include:

• Exclusive licensing deal with 3SBio valued up to $6 billion.
• $1.25 billion upfront payment boosting near-term cash flow visibility.
• Maintained Buy rating and $30 price target from BMO Capital.
• Enhanced control of Pfizer’s oncology pipeline post–Summit deal.
• Positive coverage across MarketBeat, Bloomberg, Seeking Alpha, and Benzinga.

Together, these factors have underpinned renewed investor enthusiasm in Pfizer, keeping PFE shares elevated over the past several trading sessions.